产品
编 号：F762422
分子式：C17H28ClNO2
分子量：313.86
分子式：C17H28ClNO2
分子量：313.86
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2366222-05-9
产品详情
生物活性：
SK1-I hydrochloride (BML-258 hydrochloride), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a Ki value of 10 μM. SK1-I hydrochloride shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I hydrochloride enhances autophagy and has antitumor activity.
体内研究：
Pre-treatment with SK1-I hydrochloride (BML-258 hydrochloride; intraperitoneal (i.p.) injection; once; 24 hours prior to baseline mean arterial blood pressure (MAP) measurement; 75 mg/kg) beforeanandamide (i.v. injection; two doses; 1 and 10?mg/kg) significantly decreases the hypotensive response.Animal Model:Male C57BL/6 mice (24?±?3.5?g)
Dosage:75 mg/kg
Administration:Intraperitoneal (i.p.) injection; once; 24 hours prior to baseline MAP measurement
Result:Significantly lowered baseline mean arterial blood pressure (MAP).
体外研究：
SK1-I hydrochloride (0-10 μM; 24 hours) attenuates cancer cell growth and survival in a TP53-dependent manner in HCT116 cells and HCT116 cells bearing TP53 null cancer.SK1-I hydrochloride (0-20 μM; 12 hours) induces more CASP3 cleavage in HCT116 cells, compared to HCT116 cells lacking TP53, leading to a hallmark of apoptosis.
SK1-I hydrochloride (BML-258 hydrochloride), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a Ki value of 10 μM. SK1-I hydrochloride shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I hydrochloride enhances autophagy and has antitumor activity.
体内研究：
Pre-treatment with SK1-I hydrochloride (BML-258 hydrochloride; intraperitoneal (i.p.) injection; once; 24 hours prior to baseline mean arterial blood pressure (MAP) measurement; 75 mg/kg) beforeanandamide (i.v. injection; two doses; 1 and 10?mg/kg) significantly decreases the hypotensive response.Animal Model:Male C57BL/6 mice (24?±?3.5?g)
Dosage:75 mg/kg
Administration:Intraperitoneal (i.p.) injection; once; 24 hours prior to baseline MAP measurement
Result:Significantly lowered baseline mean arterial blood pressure (MAP).
体外研究：
SK1-I hydrochloride (0-10 μM; 24 hours) attenuates cancer cell growth and survival in a TP53-dependent manner in HCT116 cells and HCT116 cells bearing TP53 null cancer.SK1-I hydrochloride (0-20 μM; 12 hours) induces more CASP3 cleavage in HCT116 cells, compared to HCT116 cells lacking TP53, leading to a hallmark of apoptosis.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备